Focused On-demand Library for Protein SERAC1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q96JX3

UPID:

SRAC1_HUMAN

Alternative names:

Serine active site-containing protein 1

Alternative UPACC:

Q96JX3; Q49AT1; Q5VTX3; Q6PKF3

Background:

Protein SERAC1, also known as Serine active site-containing protein 1, is pivotal in phosphatidylglycerol remodeling, crucial for mitochondrial function and intracellular cholesterol trafficking. It is speculated to catalyze the remodeling of phosphatidylglycerol and participate in the transacylation-acylation reaction to produce phosphatidylglycerol-36:1, and may play a role in the bis(monoacylglycerol)phosphate biosynthetic pathway.

Therapeutic significance:

SERAC1's dysfunction is linked to 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome, a disorder marked by developmental delays, sensorineural deafness, and brain abnormalities. Understanding SERAC1's role could lead to novel therapeutic strategies for this and potentially other mitochondrial and cholesterol trafficking-related diseases.